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Carboxypeptidase H (CPH) is one of several processing enzymes required for the conversion of peptide hormone precur- 
sors into their smaller active forms. In this study, high levels of CPH activity was found in a liver metastasis of a human 
ileal carcinoid which expresses /%preprotachykinin mRNA and the tachykinin neuropeptides, substance P and substance 
K. This human CPH showed properties of a zinc-metallopeptidase that is structurally similar to bovine and rat CPH. 
Immunoblots of the human ileal carcinoma with anti-bovine CPH showed that CPH activity is represented by two pro- 
teins of apparent molecular masses 57 and 55 kDa. Cell-free translation of poly(A)+ RNA followed by immunoprecipita- 
tion with anti-bovine CPH showed that human CPH mRNA encodes a precursor protein of apparent molecular mass 
75 kDa. These data demonstrate that human CPH is synthesized as a zymogen, prepro-CPH, which must be cleaved 
to form catalytically active CPH. 
Prohormone processing enzyme; Limited proteolysis; Substance P; (Human ileal carcinoid) 
1. INTRODUCTION 
Peptide hormones and peptide neurotransmit- 
ters such as adrenocorticotropic hormone (ACTH) 
[l], enkephalins [2,3], substance P [4], etc. are syn- 
thesized as large protein precursors of approx. 
IO-30 kDa which must be specifically cleaved to 
form the smaller active peptides. Carboxypep- 
tidase H (H = hormone [5]; previously referred to 
as ‘carboxypeptidase B-like’ [6-81, or ‘enkephalin 
convertase’ [9-l l]), is one of several proteases re- 
quired for peptide precursor processing. Following 
the initial cleavage of the precursor at pairs of 
basic residues (Lys-Arg, and less commonly Arg- 
Arg, Lys-Lys, or Arg-Lys sequences) by trypsin- 
like endopeptidase(s) [121, carboxypeptidase H 
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(CPH) then removes the COOH-terminal Lys 
and/or Arg extensions on the peptide. Although 
CPH resembles pancreatic carboxypeptidase B 
(CPB) in its specificity for basic amino acid 
residues, differences in the molecular properties of 
CPH compared to CPB [6-l 11, and lack of cross- 
reactivity of anti-CPH antiserum with CPB [8] 
have shown that CPH is a unique carboxypep- 
tidase that is involved in the production of a varie- 
ty of peptide hormones and neurotransmitters. 
The peptide precursors lack biological activity 
and it is only the smaller mature peptides which 
possess the ability to function as the physiologic 
mediators of cell-cell communication. Because it is 
at the step of precursor processing that inactive 
forms are converted to potent active peptides, the 
processing enzymes should be important for the 
control of peptide hormone production. Defective 
processing enzymes could lead to abnormal hor- 
mone production in endocrine or neurological 
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diseases. However, determination of the role of 
these processing enzymes in human physiology re- 
quires identification of the human isozymes that 
convert the peptide precursors to the small 
hormones. 
A liver metastasis of a human ileal carcinoid has 
been found to contain large amounts of the 
neuropeptide substance P [13]. It contains cor- 
responding high Ievels of fl-preprotachykinin 
mRNA [ 141 which encodes a 15 kDa precursor that 
must be cleaved to form substance P and substance 
K (neurokinin A) which are peptides of 11 and 10 
amino acid residues, respectively. The pairs of 
dibasic amino acid sequences within the human fi- 
preprotachykinin precursor [ 151 predict that CPH 
is required for processing and, thus, should be pre- 
sent in this tumor. In this study, we show that the 
human ileal carcinoid tumor contains high levels of 
CPH activity that possesses properties similar to 
bovine and rat CPH. Furthermore, analysis of the 
molecular forms of CPH in this tumor shows that 
CPH itself is synthesized as a zymogen that must 
be converted to the smaller active enzyme. 
2. MATERIALS AND METHODS 
2.1. Tissue homogenates 
Human ileal carcinoid tumor, derived from a liver metastasis, 
was obtained from Dr F. Sundler (University of Lund, 
Sweden). The tissue had been stored postmortem at - 80°C for 
several years. The carcinoid tumor was homogenized in 0.1 M 
sodium acetate (pH 5.7). Fresh bovine adrenal medulla 
(Biological Research and Delivery Development Services, Mt. 
Airy, MD) homogenate was prepared similarly. Samples were 
assayed for CPH activity and subjected to immunoblot 
analysis. Protein content in homogenates was determined ac- 
cording to Lowry et al. [16] with bovine serum albumin as 
standard. 
2.2. CPH assay 
CPH activity in tissue homogenates was assayed by following 
the conversion of [3H]benzoyl-Phe-Ala-Arg to [“Hlbenzoyl- 
Phe-Ala using a modification [17] of the method of Stack et al. 
[18]. This procedure measures CPH activity by taking advan- 
tage of its characteristic simulation by CoClz and inhibition by 
guanidinopropylsuccinic acid (GPSA), a zinc-metalloprotease 
inhibitor [19]. Activity was measured in the presence of [Co”] 
or [Co’+ + GPSA], CPH activity being taken as the difference. 
The reaction mixture contained, in a final volume of 60~1, 
0.1 M sodium acetate (pH 5.7), 100000 cpm [‘Hlbenzoyl-Phe- 
Ala-Arg (30 Ci/mmol, DuPont-New England Nuclear, Boston, 
MA), 3 mM Co*+ and/or 1.2 PM GPSA (a gift from Dr 
Thomas Plummer, State of New York Dept of Health, Albany, 
NY). After vortex-mixing and being left to stand on ice for 
30 min, samples were incubated at 37°C for 10 min, the reac- 
tion subsequently being arrested by the addition of 50 ~1 of 1 N 
HCI in ice. The product [‘Hlbenzoyl-Phe-Ala was extracted 
with 1.0 ml CHCll and aliquots counted in a scintillation 
counter. 
2.3. Immunoblotting 
lmmunoblot analysis of tissue homogenate was performed as 
in [S]. Homogenate samples were heated to 100°C with SDS- 
PAGE sample buffer (final concentrations: 5 mM Tris-glycine, 
3.3% ,&mercaptoethanol, 10% glycerol, 2% SDS). Samples 
were electrophoresed on 10% SDS-PAGE gels, transferred elec- 
trophoretically to nitrocellulose (0.45 gm, Schleicher and 
Schuell, Keene, NH), and probed with rabbit anti-bovine CPH 
(lot no. A(2); final dilution 1: 500). Rabbit antibody-CPH com- 
plexes were visualized with peroxidase-linked goat anti-rabbit 
immunoglobulins (Boehringer Mannheim, Indianapolis, IN). 
2.4. Isolation of poly(A)+ RNA and cell-free translation 
Frozen tumor tissue was pulverized in liquid N2 and RNA 
isolated by homogenization in 5.5 M guanidine thiocyanate, 
2.5 mM EDTA, 0.5% sarcosyl, 0.22 M ,&mercaptoethanol, 
and 20 mM Tris-HCl (pH 7.4) 1201. The slurry was passed three 
times through a 23-gauge needle and layered on a 1.5 ml CsCl- 
trifluoroacetic acid (Pharmacia, Piscataway, NJ) cushion (den- 
sity: 1.51 with 250 mM EDTA). After centrifugation in a 
Beckman SW 50.1 rotor at 36000 rpm for 16-18 h, the pelleted 
RNA was dissolved in 0.3 ml of 0.2% SDS, heated to 58°C for 
5 min and precipitated with 3 vols ethanol in the presence of 
0.4 M sodium acetate (pH 5.5). Poly(A)+-enriched RNA was 
selected using Hybond-mAP (Amersham) according to the sup- 
plier’s protocol. Aliquots of poly(A)+ RNA (l-5 yg) were 
translated with [3SS]methionine in a rabbit reticulocyte cell-free 
translation system (New England Nuclear). 
2.5. Immunoprecipitation 
lmmunoprecipitations were carried out with (0.5-2) x 
lo6 cpm %-labeled proteins as determined by trichloroacetic 
acid precipitation, Translation reaction mixtures (25-100 ~1) 
were diluted to 300~1 to give final buffer concentrations of 
0.1 M Tris-HCl (pH 7.4) with 2.6 x 1O-4 M PMSF, 1 X lo-’ M 
leupeptin, and 5 x 10e3 M iodoacetamide as protease in- 
hibitors. %-proteins were immunoprecipitated twice with nor- 
mal rabbit serum (nrs) and then with rabbit anti-CPH (lot A5) 
as follows. 
5 ~1 nrs was added to each 300 ~1 sample. Following incuba- 
tion at 4°C for 2 h with rocking, 30~1 protein A-Sepharose 
(Pharmacia) was added and samples were incubated for an ad- 
ditional hour at 4°C with rocking. Antigen-antibody-protein A- 
Sepharose complexes were pelleted by centrifugation in a 
microfuge for 5 min. The supernatant was again im- 
munoprecipitated with 5 pl nrs, followed by 5 ,ul rabbit anti- 
bovine CPH. For CPH absorption controls, anti-CPH was 
preincubated with purified soluble form of bovine pituitary 
CPH, purified according to Fricker and Snyder [lo] (the p- 
aminobenzoylarginine-Sepharose 4B affinity column was a gift 
from Dr T.H. Plummer, New York State Dept of Health) 
before addition of these components to ‘%-proteins for im- 
munoprecipitation. 
After immunoprecipitation, protein A-Sepharose pellets were 
washed with 500 gl NET buffer and 500 81 NET/NaCl (twice) 
[NET: 50 mM Tris-HC1 (pH 7.5), 150 mM NaCl, 5 mM 
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EDTA, 0.5% NP-40; NET/NaCI: NET with 1.0 M NaCI]. %- 
proteins were liberated from protein A-Sepharose by boiling in 
25 ~1 sample buffer (final concentrations: 1.25 mM Tris- 
glycine, 1% SDS, 2.5% p-mercaptoethanol, 5% glycerol). The 
supernatant was collected by pelleting the protein A-Sepha- 
rose, and subsequent analysis by 1.5% SDS-PAGE. 
Autoradiographs were scanned with a Shimadzu laser den- 
sitometer. 
3. RESULTS 
3.1. CPH activity 
The presence of high levels of p- 
preprotachykinin mRNA [14] and substance P 
peptide [13] in the human ileal carcinoid suggests 
that the presence of CPH activity is necessary for 
processing of ,8-preprotachykinin. The carcinoid 
displayed CPH activity which removed the 
COOH-terminal arginine from the substrate 
[3H]benzoyl-Phe-Ala-Arg, yielding the product 
[3H]benzoyl-Phe-Ala (fig.lA). The activity was 
stimulated I.5fold by 3 mM Co’+ under assay 
conditions of linear product formation which cor- 
A 
3- 
pg Protein Homogenate 
Fig.2. lmmunoblot of CPH in human ileal carcinoid and bovine 
adrenal medulla. (A) Immunoblots of human ileal carcinoid 
(lane 1) and bovine adrenal medulla (lane 2) utilized 16 and 
20 pg homogenate protein, respectively. The arrow denotes the 
position of the doublet detected by CPH antisera. (B) 
Densitometric scanning of (1) human ileal carcinoid and (2) 
bovine adrenal medulla immunoblots from (A). Peaks a and b 
(indicated by arrows) correspond to proteins of 57 and 55 kDa 
Fig. 1. CPH activity in human ileal carcinoma. (A) CPH activity 
assayed in tissue homogenates: (0) no additions, (0) with 
3 mM Co’+, or (A) with 3 mM Co’+ plus 1.2,uM GPSA. (B) 
Difference between Co*+-stimulated and GPSA-inhibited (in 
the presence of Co*+) CPH activities. apparent molecular mass. 
Table 1 
CPH specific activity in tissue homogenates 
Tissue CPH specific activity 
(pmol [‘Hlbenzoyl-Phe-Ala/ 
min per gg protein) 
Human carcinoid 0.13 
Human rhabdomyosarcoma 0 
Bovine adrenal medulla 0.026 
Rat adrenal medulla 0.026 
Rat posterior pituitary 0.71 
responded to 20-25% conversion of substrate to 
product. This is represented by assay of CPH pre- 
sent in less than 1 pg homogenate protein (fig.1). 
In addition, human CPH was inhibited by 1.2 ,YM 
GPSA, a zinc-metallopeptidase inhibitor. The dif- 
ference between Co’+-stimulated and GPSA- 
inhibited activity represents CPH (fig.lB). 
CPH specific activity in the carcinoid was com- 
pared with that in several other neuroendocrine 
I’ 
mm 
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tissues that synthesize enkephalins (adrenal 
medulla), and vasopressin and oxytocin (posterior 
pituitary) (table 1). The human carcinoid showed 
5-fold greater CPH specific activity than that in 
adrenal medulla of bovine or rat. CPH activity in 
the human carcinoid, however, was not as large as 
that in rat posterior pituitary. In contrast, human 
rhabdomyosarcoma (from pelvic muscle), a tissue 
which contains no peptide hormone, showed no 
CPH activity. 
3.2. Immunoblot analysis 
Characterization of CPH immunoreactive pro- 
tein in human ileal carcinoma was accomplished by 
immunoblot analysis of tissue homogenate using a 
specific rabbit anti-bovine CPH serum that has 
been previously characterized [8]. The human ileal 
carcinoid, like bovine adrenal medulla, possessed 
two immunoreactive protein bands of apparent 
molecular masses 57 and 55 kDa (fig.2). When 
similar amounts of the two tissues (16-20rg pro- 
tein) were analyzed, the human ileal carcinoid 
tissue showed less CPH immunoreactivity than 
1 2345~ 
Fig.3. Cell-free translation of poly(A)+ RNA and 
immunoprecipitation with anti-CPH. (A) Human ileal 
carcinoma mRNA was translated in a rabbit reticulocyte cell- 
free translation system and ‘%abeled proteins were 
immunoprecipitated with anti-CPH serum in the absence (lane 
1) and presence (lane 2) of partially purified bovine pituitary 
CPH. Immunoprecipitates were analyzed on 7.5% SDS-PAGE 
and autoradiographs are shown. The arrow indicates a protein 
of 75 kDa apparent molecular mass. (B) Densitometric 
scanning of lanes 1,2 from (A). These scans show that detection 
of the 75 kDa protein by the CPH antiserum is specific, since 
antiserum binding to this protein is reduced (scan of lane 2) 
when unlabeled CPH is included in the incubation mixture. 
bovine adrenal medulla, as demonstrated by the 
lower intensity of CPH immunostaining. 
3.3. Identification of zymogen form of CPH 
To compare the primary translation product of 
CPH encoded by its mRNA with the mature forms 
of CPH (apparent molecular mass: 55 and 
57 kDa), cell-free translation experiments were 
performed. Poly(A)+ RNA isolated from the 
human ileal carcinoid was translated with 
[35S]methionine in a rabbit reticulocyte cell-free 
translation system, radiolabeled proteins being im- 
munoprecipitated with anti-bovine CPH serum. 
Analysis of the immunoprecipitates by SDS-PAGE 
and autoradiography revealed that CPH is initially 
synthesized as a precursor protein of apparent 
molecular mass 75 kDa. 
4. DISCUSSION 
Previous investigations have characterized CPH 
in bovine and rat species. CPH has not been iden- 
tified in human tissues. Here, we have 
demonstrated that a human carcinoid contains 
high levels of CPH activity, one of several process- 
ing enzymes required for conversion of the & 
preprotachykinin precursor to the smaller active 
neuropeptides, substance P and substance K, that 
are present in this tissue. Furthermore, analysis of 
the molecular forms of CPH shows that it is first 
synthesized as a zymogen that must be cleaved to 
form mature active CPH. 
The carcinoid contains levels of CPH activity 
which are comparable to those of other 
neuropeptide-synthesizing tissues. It contains 
5-fold greater CPH specific activity than rat or 
bovine adrenal medulla which possess considerable 
amounts of proenkephalin peptides. On the other 
hand, it contains less CPH activity than rat 
posterior pituitary where high levels of CPH activi- 
ty are present for the production of vasopressin, 
oxytocin, and enkephalin peptides [ 121. 
Human CPH was stimulated by Co’+, and the 
Co’+-stimulated activity was completely inhibited 
by GPSA, a zinc-metallopeptidase inhibitor [ 191. 
These data show that human CPH, like the bovine 
and rat forms, is a zinc-metallopeptidase. 
The presence of CPH immunoreactivity in 
human tissue, as detected with an anti-bovine CPH 
antibody, suggests that human CPH shares struc- 
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tural similarities and some homologous amino acid 
sequences with bovine CPH. Using anti-bovine 
CPH antibody, CPH immunoreactivity has also 
been reported in rat pituitary [S] and in striatum of 
cats and monkeys [22]. Thus, CPH in several 
species appears to be a structurally similar enzyme 
protein. 
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Comparison of CPH catalytic activity and im- 
munoreactivity in equivalent amounts of tissue 
homogenates shows that the carcinoid possesses 
levels of CPH specific activity and immunoreac- 
tivity that are S- and approx. 0.25-fold of the cor- 
responding values observed in bovine adrenal 
medulla. These data suggest hat CPH in the car- 
cinoid possesses greater catalytic activity per unit 
number of enzyme molecules than that in bovine 
adrenal medulla. This conclusion would be valid if 
the CPH antiserum has identical affinity for 
human and bovine isozymes. Alternatively, if 
human and bovine CPH possess some structural 
differences, the antiserum may have different af- 
finities for the two forms. In this case, conclusions 
concerning the levels of CPH protein in the two 
species must await the determination of human 
and bovine CPH structures. 
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